Aegerion Pharmaceuti
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
07 oct. 2015 16h15 HE | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 07, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Observes Familial Hypercholesterolemia Awareness Day
24 sept. 2015 09h25 HE | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Announces Presentation at the Leerink Rare Disease Roundtable
23 sept. 2015 16h15 HE | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Donald K. Stern, Esq
Donald K. Stern, Esq. Appointed to Aegerion Pharmaceuticals' Board of Directors
18 sept. 2015 07h50 HE | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 18, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
14 sept. 2015 17h00 HE | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
12 août 2015 08h30 HE | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Announces Second Quarter 2015 Financial Results
05 août 2015 16h10 HE | Aegerion Pharmaceuticals, Inc.
- Company records $64.2 million in total net product sales - - JUXTAPID® net product sales were $57.1 million in the second quarter of 2015, 96% from prescriptions written in the U.S. - -...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Announces Leadership Changes to Support the Next Stage of Growth
27 juil. 2015 08h00 HE | Aegerion Pharmaceuticals, Inc.
Company Reports Preliminary Second Quarter 2015 Total Net Product Sales of Between $63 and $64 Million and Preliminary Cash and Cash Equivalents of Approximately $82 Million as of June 30,...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
13 juil. 2015 16h10 HE | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., July 13, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Appoints Gregory Perry as Chief Financial Officer
25 juin 2015 07h30 HE | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 25, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...